Cargando…

Female Sex as a Thromboembolic Risk Factor in the Era of Nonvitamin K Antagonist Oral Anticoagulants

Sex-specific differences have been definitively demonstrated in cardiovascular (CV) diseases. These differences can also impact on the effects of CV therapies. Female sex is recognized as an independent predictor of thromboembolic risk, particularly in older patients. Most of strokes are due to atri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gallù, Mariacarla, Marrone, Giulia, Legramante, Jacopo Maria, De Lorenzo, Antonino, Di Daniele, Nicola, Noce, Annalisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336195/ https://www.ncbi.nlm.nih.gov/pubmed/32684980 http://dx.doi.org/10.1155/2020/1743927

Ejemplares similares

Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in
por: Blann, Andrew
Publicado: (2015)

Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal
por: Brown, Karen S., et al.
Publicado: (2016)

Tooth extraction in patients taking nonvitamin K antagonist oral anticoagulants
por: Morimoto, Yoshinari, et al.
Publicado: (2016)

Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment
por: Turpie, Alexander G.G., et al.
Publicado: (2017)

Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants
por: Sarah, Lessire, et al.
Publicado: (2014)

A Comparison among Nonvitamin K Antagonist Oral Anticoagulants in Asian Patients with Venous Thromboembolism: A Multi-Institutional Study
por: Tsai, Ming-Lung, et al.
Publicado: (2022)

Erratum to “Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants”
por: Lessire, Sarah, et al.
Publicado: (2014)

Tackling Nonatrial Fibrillation Diseases Using Nonvitamin K Antagonist Oral Anticoagulant: by What and for Whom?
por: Kim, Jong S.
Publicado: (2019)

The Importance of Appropriate Dosing of Nonvitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation
por: Beyer-Westendorf, Jan, et al.
Publicado: (2021)

Patient Preferences for Nonvitamin K Antagonist Oral Anticoagulants in Stroke Prevention: A Multicountry Discrete Choice Experiment
por: Wilke, Thomas, et al.
Publicado: (2019)

Erythrocyte glutathione transferase in kidney transplantation: a probe for kidney detoxification efficiency
por: Bocedi, Alessio, et al.
Publicado: (2018)

Real‐world use of nonvitamin K antagonist oral anticoagulant in atrial fibrillation patients with liver disease: A meta‐analysis
por: Dai, Qixin, et al.
Publicado: (2020)

Effectiveness and Safety of Nonvitamin K Oral Anticoagulants Rivaroxaban and Apixaban in Patients with Venous Thromboembolism: A Meta-Analysis of Real-World Studies
por: Wu, Olivia, et al.
Publicado: (2022)

Helsinki experience on nonvitamin K oral anticoagulants for treating cervical artery dissection
por: Mustanoja, Satu, et al.
Publicado: (2015)

The change of renal functions after nonvitamin K oral anticoagulants in patients with atrial fibrillation
por: Chantrarat, Thoranis, et al.
Publicado: (2021)

Nonvitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients and Risk of Dementia: A Nationwide Propensity‐Weighted Cohort Study
por: Søgaard, Mette, et al.
Publicado: (2019)

Difference between the Upper and the Lower Gastrointestinal Bleeding in Patients Taking Nonvitamin K Oral Anticoagulants
por: Maruyama, Kyohei, et al.
Publicado: (2018)

Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects
por: Parasrampuria, Dolly A., et al.
Publicado: (2015)

Optimal nonvitamin K antagonist oral anticoagulant therapy in a warfarin-sensitive patient after left atrial appendage closure: A case report
por: Shen, Long, et al.
Publicado: (2018)

Impact of Reduced-Dose Nonvitamin K Antagonist Oral Anticoagulants on Outcomes Compared to Warfarin in Korean Patients with Atrial Fibrillation: A Nationwide Population-Based Study
por: Han, Sola, et al.
Publicado: (2021)

Nonvitamin K oral anticoagulants with proton pump inhibitor cotherapy ameliorated the risk of upper gastrointestinal bleeding
por: Chaiyana, Parata, et al.
Publicado: (2023)

MOSH Syndrome (Male Obesity Secondary Hypogonadism): Clinical Assessment and Possible Therapeutic Approaches
por: De Lorenzo, Antonino, et al.
Publicado: (2018)

Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS(2) score ⩾ 2
por: Fernandez, Maria M, et al.
Publicado: (2015)

Considerations for long-term anticoagulant therapy in patients with venous thromboembolism in the novel oral anticoagulant era
por: Toth, Peter P
Publicado: (2016)

Geographic Variations in the Quality of Oral Anticoagulation With Vitamin K Antagonists in the Era of New Anticoagulants
por: Fauchier, Laurent, et al.
Publicado: (2013)

Outcomes of 4-factor Prothrombin Complex Concentrate in Patients With Liver Disease and Nonvitamin K Antagonist-Related Coagulopathy: A Retrospective Study
por: Dodhiawala, Paarth B., et al.
Publicado: (2023)

Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants
por: Weitz, Jeffrey I., et al.
Publicado: (2017)

Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants
por: Qureshi, Waqas, et al.
Publicado: (2016)

Clinical outcomes of nonvitamin K oral anticoagulants and acenocoumarol for stroke prevention in contemporary practice: A population‐based propensity‐weighted cohort study
por: Rodríguez‐Bernal, Clara L., et al.
Publicado: (2020)

Sex Differences in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism
por: Blanco-Molina, Angeles, et al.
Publicado: (2014)

Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolism
por: Goldstein, Patrick, et al.
Publicado: (2013)

Effective management of venous thromboembolism in the community: non-vitamin K antagonist oral anticoagulants
por: Patel, Raj
Publicado: (2016)

Potential Cardiovascular and Metabolic Beneficial Effects of ω-3 PUFA in Male Obesity Secondary Hypogonadism Syndrome
por: Noce, Annalisa, et al.
Publicado: (2020)

Prevalence of nonvitamin, nonmineral supplement usage among students in a Turkish university
por: Ayranci, Unal, et al.
Publicado: (2005)

Influence of Mediterranean Diet on Human Gut Microbiota
por: Merra, Giuseppe, et al.
Publicado: (2020)

The Onco-Nephrology Field: The Role of Personalized Chemotherapy to Prevent Kidney Damage
por: Noce, Annalisa, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Venous Thromboembolism in China
por: Sun, Ke-Xin, et al.
Publicado: (2021)

Efficacy and safety of non-vitamin K antagonist oral anticoagulants for venous thromboembolism: a meta-analysis
por: Zhuang, Yan, et al.
Publicado: (2021)

Correlation between Chest Computed Tomography Score and Laboratory Biomarkers in the Risk Stratification of COVID-19 Patients Admitted to the Emergency Department
por: D’Agostini, Cartesio, et al.
Publicado: (2023)

Nonvitamin, Nonmineral Dietary Supplement Use among Adults with Fibromyalgia: United States, 2007–2012
por: Feinberg, Termeh, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_f6fou7v1559vcp2q4rcl2brfo3